Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADG206 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ADG206 dose escalation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ADG206 | DRUG | All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years. |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status ≤1. * Subjects with advanced or metastatic solid tumors (except thymic tumors), which have progressed after all standard therapies, or no further standard therapies exists. * At least 1 measurable lesion per Response...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ADG206 is an investigational small molecule being developed for the treatment of advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with advanced or metastatic solid tumors who are at least 18 years old.
ADG206 targets CD137, a protein involved in immune response. By targeting CD137, ADG206 is designed to modulate the immune system's activity against cancer cells. This mechanism is being evaluated in the context of advanced or metastatic solid tumors, where the drug aims to enhance the body's ability to fight the disease.
ADG206 is being developed by Adagene Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol ADAG. The company is conducting clinical trials to evaluate the safety and efficacy of ADG206 in patients with advanced or metastatic solid tumors.
ADG206 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of ADG206 in patients with advanced or metastatic solid tumors.
ADG206 is being studied in a Phase 1 clinical trial with the identifier NCT05614258. The trial, titled "Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors," is active but not recruiting participants. It is enrolling patients in Australia and has a target enrollment of 14 participants.
ADG206 is a distinct investigational small molecule that targets CD137. While other drugs may also target CD137, ADG206 is a unique asset developed by Adagene Inc. Its specific chemical structure and properties differentiate it from other CD137-targeting agents, and it is being evaluated independently in clinical trials.